BAM
DFTX

Belpointe Asset Management’s Definium Therapeutics DFTX Stock Holding History

Belpointe Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-604
Closed -$1.91K – 2257
2023
Q1 		$1.91K Buy
604
+14
+2% +$47 ﹤0.01% 3312
2022
Q4 		$1.3K Buy
+590
New +$1.64K ﹤0.01% 3383

Other funds holding DFTX

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Belpointe Asset Management's DFTX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Definium Therapeutics (DFTX) in Q2 2023, closing a stake of 604 shares — an estimated $1.91K sold.

Belpointe Asset Management first reported a position in DFTX in Q4 2022 and held it in 2 quarters. The position peaked at $1.91K in Q1 2023. 84 funds tracked by Wall St. Rank hold DFTX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Definium Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 604 Definium Therapeutics shares in Q2 2023, an estimated $1.91K.
  • Belpointe Asset Management first reported a position in Definium Therapeutics in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Definium Therapeutics position peaked at $1.91K in Q1 2023.
  • 84 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.